A new CF treatment known as VX-770 will be a groundbreaking medicine if approved by the U.S. Food and Drug Administration, says Bloomberg Businessweek in this week's edition.
According to the article, VX-770 will be first pill designed to repair a
VX-770 is in the third and final stage of testing required for
In a study of VX-770 released in February, the drug increased
VX-770 is designed for a mutation, G551D, carried by about four percent of people with CF.
The magazine quotes Francis Collins, director of the National Institutes of Health and co-discoverer of the CF gene: “Discovering the genetic cause of a disease can lead you toward a therapy you never would have thought of otherwise."
Read the full Businessweek story on VX-770.